WHO Guideline on Antenatal Care (2016)

Özge Tunçalp, MD PhD
Scientist, HRP/RHR

Reproductive Health and Research (RHR)
Nutrition for Health and Development (NHD)
Maternal, Newborn, Child and Adolescent Health (MCA)
Outline

- Background
- Development of the WHO ANC guideline
- Recommendations
- What's new – Malaria in the context of ANC
BACKGROUND
ANC is critical

Through timely and appropriate evidence-based actions related to health promotion, disease prevention, screening, and treatment

- Reduces complications from pregnancy and childbirth
- Reduces stillbirths and perinatal deaths
- Integrated care delivery throughout pregnancy
Previously: The 4-visit WHO ANC model

- Involves specific evidence-based interventions for all women
- Carried out at four critical times
- Also known as the Focused Antenatal Care Model (FANC)
- Part of Pregnancy, Childbirth, Postpartum and Newborn Care (PCPNC)
QUALITY throughout the continuum of care

WHO envisions a world where “every pregnant woman and newborn receives quality care throughout the pregnancy, childbirth and the postnatal period”.

- Prioritizes **person-centred health and well-being**:
  - Reducing mortality and morbidity
  - Providing respectful care that takes into account woman’s views
  - Optimizing service delivery within health systems
Women’s views

Women want a Positive Pregnancy Experience from ANC

- A healthy pregnancy for mother and baby (including preventing or treating risks, illness and death)
- Physical and sociocultural normality during pregnancy
- Effective transition to positive labour and birth
- Positive motherhood (including maternal self-esteem, competence and autonomy)

Medical care; relevant and timely information; emotional support and advice


DEVELOPMENT OF THE GUIDELINE
The 2016 ANC guideline

- Essential core package of ANC that all pregnant women and adolescent girls should receive

- With the flexibility to employ different options based on the context of different countries
  - What is the content of the model/package?
  - Who provides care?
  - Where is the care provided?
  - How is the care provided to meet the needs of the users?

- Complement existing WHO guidance on complications during pregnancy

Overarching questions

- **What** are the evidence-based practices during ANC that improved outcomes and lead to positive pregnancy experience?

- **How** should these practices be delivered?
## Methodology and assessment of evidence

<table>
<thead>
<tr>
<th>Work streams</th>
<th>Methodology</th>
<th>Assessment of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual interventions for clinical practices (n=37)</td>
<td>Effectiveness reviews, systematic reviews</td>
<td>GRADE</td>
</tr>
<tr>
<td>Antenatal testing (n=2)</td>
<td>Test accuracy reviews</td>
<td>GRADE</td>
</tr>
<tr>
<td>Barriers and facilitators to access to and provision of ANC (n=2)</td>
<td>Qualitative evidence synthesis</td>
<td>GRADE-CERQual</td>
</tr>
<tr>
<td>Health systems interventions to improve the utilization and quality of ANC (n=6)</td>
<td>Effectiveness reviews</td>
<td>GRADE</td>
</tr>
<tr>
<td>Large scale WHO ANC model (4-visit) case studies</td>
<td>Mixed-methods review, focusing on contextual and health system factors affecting implementation</td>
<td>N/A</td>
</tr>
</tbody>
</table>
The DECIDE framework

- Three technical consultations with guideline development group (October 2015-March 2016)
- Collaborative effort between WHO departments, methodologists and different groups of experts

http://ietd.epistemonikos.org/
Types of recommendations

- We recommend the option
- We recommend this option under certain conditions
  - Only in the context of rigorous research
  - Only with targeted monitoring and evaluation
  - Only in specific contexts
- We do not recommend this option
Recommendations on ANC

49 recommendations were grouped into five topic areas:

A. Nutritional interventions (14)
B. Maternal and fetal assessment (13)
C. Preventive measures (7)
D. Interventions for common physiological symptoms (6)
E. Health systems interventions to improve the utilization and quality of ANC (9)

Including 10 recommendations relevant to routine ANC from other WHO guidelines
RECOMMENDATIONS
# A. Nutritional interventions - 1

<table>
<thead>
<tr>
<th><strong>A.1.1:</strong> Counselling about healthy eating and keeping physically active during pregnancy is recommended for pregnant women to stay healthy and to prevent excessive weight gain during pregnancy.</th>
<th><strong>Recommended</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A.1.2:</strong> In undernourished populations, nutrition education on increasing daily energy and protein intake is recommended for pregnant women to reduce the risk of low-birth-weight neonates.</td>
<td><strong>Context-specific recommendation</strong></td>
</tr>
<tr>
<td><strong>A.1.3:</strong> In undernourished populations, balanced energy and protein dietary supplementation is recommended for pregnant women to reduce the risk of stillbirths and small-for-gestational-age neonates.</td>
<td><strong>Context-specific recommendation</strong></td>
</tr>
<tr>
<td><strong>A.1.4:</strong> In undernourished populations, high-protein supplementation is not recommended for pregnant women to improve maternal and perinatal outcomes.</td>
<td><strong>Not recommended</strong></td>
</tr>
</tbody>
</table>
### A. Nutritional interventions -2

<table>
<thead>
<tr>
<th>A.2.1: <strong>Daily oral iron and folic acid supplementation</strong> with 30 mg to 60 mg of elemental iron and 400 µg (0.4 mg) of folic acid is recommended for pregnant women to prevent maternal anaemia, puerperal sepsis, low birth weight, and preterm birth.</th>
<th><strong>Recommended</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>A.2.2: <strong>Intermittent oral iron and folic acid supplementation</strong> with 120 mg of elemental iron and 2800 µg (2.8 mg) of folic acid once weekly is recommended for pregnant women to improve maternal and neonatal outcomes if daily iron is not acceptable due to side-effects, and in populations with an anaemia prevalence among pregnant women of less than 20%.</td>
<td><strong>Context-specific recommendation</strong></td>
</tr>
<tr>
<td>A.3: In populations with low dietary calcium intake, <strong>daily calcium supplementation</strong> (1.5–2.0 g oral elemental calcium) is recommended for pregnant women to reduce the risk of pre-eclampsia.</td>
<td><strong>Context-specific recommendation</strong></td>
</tr>
<tr>
<td>A.4: <strong>Vitamin A supplementation</strong> is only recommended for pregnant women in areas where vitamin A deficiency is a severe public health problem, to prevent night blindness.</td>
<td><strong>Context-specific recommendation</strong></td>
</tr>
<tr>
<td>Nutritional interventions - 3</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td></td>
</tr>
<tr>
<td>A.5: <strong>Zinc supplementation</strong> for pregnant women is only recommended in the context of rigorous research.</td>
<td><strong>Context-specific recommendation (research)</strong></td>
</tr>
<tr>
<td>A.6: <strong>Multiple micronutrient supplementation</strong> is not recommended for pregnant women to improve maternal and perinatal outcomes.</td>
<td><strong>Not recommended</strong></td>
</tr>
<tr>
<td>A.7: <strong>Vitamin B6 (pyridoxine) supplementation</strong> is not recommended for pregnant women to improve maternal and perinatal outcomes.</td>
<td><strong>Not recommended</strong></td>
</tr>
<tr>
<td>A.8: <strong>Vitamin E and C supplementation</strong> is not recommended for pregnant women to improve maternal and perinatal outcomes.</td>
<td><strong>Not recommended</strong></td>
</tr>
<tr>
<td>A.9: <strong>Vitamin D supplementation</strong> is not recommended for pregnant women to improve maternal and perinatal outcomes.</td>
<td><strong>Not recommended</strong></td>
</tr>
<tr>
<td>A.10: For pregnant women with high daily caffeine intake (more than 300 mg per day), lowering <strong>daily caffeine intake</strong> during pregnancy is recommended to reduce the risk of pregnancy loss and low-birth-weight neonates.</td>
<td><strong>Context-specific recommendation</strong></td>
</tr>
</tbody>
</table>
# B.1. Maternal assessment

<table>
<thead>
<tr>
<th>B.1.1: Full blood count testing is the recommended method for diagnosing <strong>anaemia</strong> in pregnancy. In settings where full blood count testing is not available, on-site haemoglobin testing with a haemoglobinometer is recommended over the use of the haemoglobin colour scale as the method for diagnosing anaemia in pregnancy.</th>
<th>Context-specific recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1.2: Midstream urine culture is the recommended method for diagnosing <strong>asymptomatic bacteriuria (ASB)</strong> in pregnancy. In settings where urine culture is not available, on-site midstream urine Gram-staining is recommended over the use of dipstick tests as the method for diagnosing ASB in pregnancy.</td>
<td>Context-specific recommendation</td>
</tr>
<tr>
<td>B.1.3: <strong>Clinical enquiry about the possibility of intimate partner violence</strong> (IPV) should be strongly considered at antenatal care visits when assessing conditions that may be caused or complicated by IPV in order to improve clinical diagnosis and subsequent care, where there is the capacity to provide a supportive response (including referral where appropriate) and where the WHO minimum requirements are met.</td>
<td>Context-specific recommendation</td>
</tr>
</tbody>
</table>
B.1. Maternal assessment - 2

<table>
<thead>
<tr>
<th>B.1.4: <strong>Hyperglycaemia</strong> first detected at any time during pregnancy should be classified as either gestational diabetes mellitus (GDM) or diabetes mellitus in pregnancy, according to WHO criteria.</th>
<th>Recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1.5: Health-care providers should ask all pregnant women about their <strong>tobacco use</strong> (past and present) and exposure to second-hand smoke as early as possible in the pregnancy and at every antenatal care visit.</td>
<td>Recommended</td>
</tr>
<tr>
<td>B.1.6: Health-care providers should ask all pregnant women about their use of <strong>alcohol and other substances</strong> (past and present) as early as possible in the pregnancy and at every antenatal care visit.</td>
<td>Recommended</td>
</tr>
<tr>
<td>B.1.7: In high-prevalence settings, provider-initiated testing and counselling (PITC) for <strong>HIV</strong> should be considered a routine component of the package of care for pregnant women in all antenatal care settings. In low-prevalence settings, PITC can be considered for pregnant women in antenatal care settings as a key component of the effort to eliminate mother-to-child transmission of HIV, and to integrate HIV testing with <strong>syphilis</strong>, viral or other key tests, as relevant to the setting, and to strengthen the underlying maternal and child health systems.</td>
<td>Recommended</td>
</tr>
<tr>
<td>B.1.8: In settings where the <strong>tuberculosis</strong> (TB) prevalence in the general population is 100/100 000 population or higher, systematic screening for active TB should be considered for pregnant women as part of antenatal care.</td>
<td>Context-specific recommendation</td>
</tr>
</tbody>
</table>
## B.2. Fetal assessment

<table>
<thead>
<tr>
<th>B.2.1: Daily fetal movement counting, such as with “count-to-ten” kick charts, is only recommended in the context of rigorous research.</th>
<th>Context-specific recommendation (research)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.2.2: Replacing abdominal palpation with symphysis-fundal height (SFH) measurement for the assessment of fetal growth is not recommended to improve perinatal outcomes. A change from what is usually practiced (abdominal palpation or SFH measurement) in a particular setting is not recommended.</td>
<td>Context-specific recommendation</td>
</tr>
<tr>
<td>B.2.3: Routine antenatal cardiotocography is not recommended for pregnant women to improve maternal and perinatal outcomes.</td>
<td>Not recommended</td>
</tr>
<tr>
<td>B.2.4: One ultrasound scan before 24 weeks of gestation (early ultrasound) is recommended for pregnant women to estimate gestational age, improve detection of fetal anomalies and multiple pregnancies, reduce induction of labour for post-term pregnancy, and improve a woman’s pregnancy experience.</td>
<td>Recommended</td>
</tr>
<tr>
<td>B.2.5: Routine Doppler ultrasound examination is not recommended for pregnant women to improve maternal and perinatal outcomes.</td>
<td>Not recommended</td>
</tr>
</tbody>
</table>
# C. Preventive measures - 1

| C.1: | A seven-day antibiotic regimen is recommended for all pregnant women with **asymptomatic bacteriuria (ASB)** to prevent persistent bacteriuria, preterm birth and low birth weight. | **Recommended** |
| C.2: | Antibiotic prophylaxis is only recommended to prevent **recurrent urinary tract infections** in pregnant women in the context of rigorous research. | **Context-specific recommendation (research)** |
| C.3: | Antenatal prophylaxis with **anti-D immunoglobulin** in non-sensitized Rh-negative pregnant women at 28 and 34 weeks of gestation to prevent RhD alloimmunization is only recommended in the context of rigorous research. | **Context-specific recommendation (research)** |
| C.4: | In endemic areas, **preventive anthelminthic treatment** is recommended for pregnant women after the first trimester as part of worm infection reduction programmes. | **Context-specific recommendation** |
| C.5: | **Tetanus toxoid vaccination** is recommended for all pregnant women, depending on previous tetanus vaccination exposure, to prevent neonatal mortality from tetanus. | **Recommended** |
C. Preventive measures - 2

C.6: In malaria-endemic areas in Africa, intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) is recommended for all pregnant women. Dosing should start in the second trimester, and doses should be given at least one month apart, with the objective of ensuring that at least three doses are received.

C.7: Oral pre-exposure prophylaxis (PrEP) containing tenofovir disoproxil fumarate (TDF) should be offered as an additional prevention choice for pregnant women at substantial risk of HIV infection as part of combination prevention approaches.
## D. Common physiological symptoms

<table>
<thead>
<tr>
<th>D.1: Ginger, chamomile, vitamin B6 and/or acupuncture are recommended for the relief of <strong>nausea</strong> in early pregnancy, based on a woman’s preferences and available options.</th>
<th><strong>Recommended</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>D.2: Advice on diet and lifestyle is recommended to prevent and relieve <strong>heartburn</strong> in pregnancy. Antacid preparations can be offered to women with troublesome symptoms that are not relieved by lifestyle modification.</td>
<td><strong>Recommended</strong></td>
</tr>
<tr>
<td>D.3: Magnesium, calcium or non-pharmacological treatment options can be used for the relief of <strong>leg cramps</strong> in pregnancy, based on a woman’s preferences and available options.</td>
<td><strong>Recommended</strong></td>
</tr>
<tr>
<td>D.4: Regular exercise throughout pregnancy is recommended to prevent <strong>low back and pelvic pain</strong>. There are a number of different treatment options that can be used, such as physiotherapy, support belts and acupuncture, based on a woman’s preferences and available options.</td>
<td><strong>Recommended</strong></td>
</tr>
<tr>
<td>D.5: Wheat bran or other fibre supplements can be used to relieve <strong>constipation</strong> in pregnancy if the condition fails to respond to dietary modification, based on a woman’s preferences and available options.</td>
<td><strong>Recommended</strong></td>
</tr>
<tr>
<td>D.6: Non-pharmacological options, such as compression stockings, leg elevation and water immersion, can be used for the management of <strong>varicose veins and oedema</strong> in pregnancy, based on a woman’s preferences and available options.</td>
<td><strong>Recommended</strong></td>
</tr>
</tbody>
</table>
### E. Health systems interventions to improve the utilization and quality of ANC – 1

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E.1</strong>: It is recommended that each pregnant woman carries her own case notes during pregnancy to improve continuity, quality of care and her pregnancy experience.</td>
<td><strong>Recommended</strong></td>
</tr>
<tr>
<td><strong>E.2</strong>: Midwife-led continuity-of-care models, in which a known midwife or small group of known midwives supports a woman throughout the antenatal, intrapartum and postnatal continuum, are recommended for pregnant women in settings with well functioning midwifery programmes.</td>
<td><strong>Context-specific recommendation</strong></td>
</tr>
<tr>
<td><strong>E.3</strong>: Group antenatal care provided by qualified health-care professionals may be offered as an alternative to individual antenatal care for pregnant women in the context of rigorous research, depending on a woman’s preferences and provided that the infrastructure and resources for delivery of group antenatal care are available.</td>
<td><strong>Context-specific recommendation (research)</strong></td>
</tr>
</tbody>
</table>
E. Health systems interventions to improve the utilization and quality of ANC – 2

<table>
<thead>
<tr>
<th>E.4.1: The implementation of community mobilization through facilitated participatory learning and action (PLA) cycles with women’s groups is recommended to improve maternal and newborn health, particularly in rural settings with low access to health services. Participatory women’s groups represent an opportunity for women to discuss their needs during pregnancy, including barriers to reaching care, and to increase support to pregnant women.</th>
<th>Context-specific recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>E.4.2: Packages of interventions that include household and community mobilization and antenatal home visits are recommended to improve antenatal care utilization and perinatal health outcomes, particularly in rural settings with low access to health services.</td>
<td>Context-specific recommendation</td>
</tr>
</tbody>
</table>
### E. Health systems interventions to improve the utilization and quality of ANC – 3

<table>
<thead>
<tr>
<th>E.5.1: Task shifting the promotion of health-related behaviours for maternal and newborn health to a broad range of cadres, including lay health workers, auxiliary nurses, nurses, midwives and doctors is recommended.</th>
<th><strong>Recommended</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>E.5.2: Task shifting the distribution of recommended nutritional supplements and intermittent preventative treatment in pregnancy (IPTp) for malaria prevention to a broad range of cadres, including auxiliary nurses, nurses, midwives and doctors is recommended.</td>
<td><strong>Recommended</strong></td>
</tr>
<tr>
<td>E.6: Policy-makers should consider educational, regulatory, financial, and personal and professional support interventions to recruit and retain qualified health workers in rural and remote areas.</td>
<td><strong>Context-specific recommendation</strong></td>
</tr>
</tbody>
</table>
E. Health systems interventions to improve the utilization and quality of ANC – 4

E.7: Antenatal care models with a **minimum of eight contacts** are recommended to reduce perinatal mortality and improve women’s experience of care.
WHAT’S NEW?

MALARIA IN THE CONTEXT OF ANC
ANC models with a minimum of 8 contacts

- E.7: Antenatal care models with a minimum of eight contacts are recommended to reduce perinatal mortality and improve women’s experience of care.

<table>
<thead>
<tr>
<th>WHO FANC model</th>
<th>2016 WHO ANC model</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First trimester</strong></td>
<td></td>
</tr>
<tr>
<td>Visit 1: 8-12 weeks</td>
<td>Contact 1: up to 12 weeks</td>
</tr>
<tr>
<td><strong>Second trimester</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Visit 2: 24-26 weeks | Contact 2: 20 weeks  
|                       | Contact 3: 26 weeks  |
| **Third trimester** |                      |
| Visit 3: 32 weeks | Contact 4: 30 weeks  
| Visit 4: 36-38 weeks | Contact 5: 34 weeks  
|                       | Contact 6: 36 weeks  
|                       | Contact 7: 38 weeks  
|                       | Contact 8: 40 weeks  |
| Return for delivery at 41 weeks if not given birth. |
Contact versus visit

- The guideline uses the term ‘contact’ - it implies an active connection between a pregnant woman and a health care provider that is not implicit with the word ‘visit’.
  - **quality** care including medical care, support and timely and relevant information

- In terms of the operationalization of this recommendation, ‘contact’ can take place at the facility or at community level
  - be adapted to local context through health facilities or community outreach services

- ‘Contact’ helps to facilitate context-specific recommendations
  - Interventions (such as malaria, tuberculosis)
  - Health system (such as task shifting)
ANC model – positive pregnancy experience

Overarching aim

To provide pregnant women with respectful, individualized, person-centred care at every contact, with implementation of effective clinical practices (interventions and tests), and provision of relevant and timely information, and psychosocial and emotional support, by practitioners with good clinical and interpersonal skills within a well functioning health system.
Effective implementation of ANC requires

- Health systems approach and strengthening
  - Continuity of care
  - Integrated service delivery
  - Improved communication with, and support for women
  - Availability of supplies and commodities
  - Empowered health care providers
    - Recruitment and retention of staff in rural and remote areas
    - Capacity building
C.6: Intermittent preventive treatment of malaria in pregnancy (IPTp)

RECOMMENDATION C.6: In malaria-endemic areas in Africa, Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) is recommended for all pregnant women. Dosing should start in the second trimester, and doses should be given at least one month apart, with the objective of ensuring that at least three doses are received. (Context-specific recommendation)

Remarks

- This recommendation has been integrated from the WHO Guidelines for the treatment of malaria (2015), where it is considered to be a strong recommendation based on high-quality evidence (153).
- Malaria infection during pregnancy is a major public health problem, with substantial risks for the mother, her fetus and the newborn. WHO recommends a package of interventions for preventing and controlling malaria during pregnancy, which includes promotion and use of insecticide-treated nets, appropriate case management with prompt, effective treatment, and, in areas with moderate to high transmission of Plasmodium falciparum, administration of IPTp-SP (153).
- The high-quality evidence supporting this recommendation was derived from a systematic review of seven RCTs conducted in malaria-endemic countries, which shows that three or more doses of sulfadoxine-pyrimethamine (SP) is associated with reduced maternal parasitaemia, fewer low-birthweight infants and increased mean birth weight compared with two doses only (154).
- The malaria GDG noted that most evidence was derived from women in their first and second pregnancies; however, the limited evidence on IPTp-SP from women in their third and subsequent pregnancies was consistent with benefit (153).
- To ensure that pregnant women in endemic areas start IPTp-SP as early as possible in the second trimester, policy-makers should ensure health system contact with women at 13 weeks of gestation. Policy-makers could also consider supplying women with their first SP dose at the first ANC visit with instructions about the date (corresponding to 13 weeks of gestation) on which the medicine should be taken.
- SP acts by interfering with folic acid synthesis in the malaria parasite, thereby inhibiting its life-cycle. There is some evidence that high doses of supplemented folic acid (i.e. 5 mg daily or more) may interfere with the efficacy of SP in pregnancy (155). Countries should ensure that they procure and distribute folic acid supplements for antenatal use at the recommended antenatal dosage (i.e. 0.4 mg daily).
- The malaria GDG noted that there is insufficient evidence on the safety, efficacy and pharmacokinetics of most antimalarial agents in pregnancy, particularly during the first trimester (153).
- Detailed evidence and guidance related to the recommendation can be found in the 2015 guidelines (153), available at: http://www.who.int/malaria/publications/atoz/9789241549127/en/
Topics highlighted

- Training of IPTp-SP
- 2016 ANC model contact schedule with timelines for implementation of Mip interventions
- Frequency of IPTp-SP
- Sourcing of quality assured SP
- ITN use
- Effective case management
- Women living with HIV
- Iron and folic acid supplementation
Dissemination, implementation, research

- Development of tools to support adaptation and implementation at the country level
- Development of indicators
- Implementation research/design of ANC in countries
- Living guideline/online

- **Regional workshops**
  - 17 November 2016: West & Central Africa (Burkina Faso)
  - 27-28 April 2017: Eastern Europe & Central Asia (Georgia)
  - 28-30 June 2017: South and East Africa (Rwanda)
  - January 2018: SEARO (planned)

- Translation of the guideline (Russian, French ongoing)
Relevant links – 1

About the guidelines:

South Africa story from the field:

The guideline
www.who.int/reproductivehealth/publications/maternal_perinatal_health/anc-positive-pregnancy-experience/en/

Press release
Relevant links – 2

Infographics

Many thanks to...

- **WHO Steering Group**
  - A. Metin Gülmezoglu (RHR), Matthews Mathai (MCA), Olufemi Oladapo (RHR), Juan Pablo Peña-Rosas (NHD), Özge Tunçalp (RHR)

- **Members of the GDG**

- **WHO regional advisors**
  - Karima Gholbzouri, Gunta Lazdane, Bremen de Mucio, Mari Nagai, Leopold Ouedraogo, Neena Raina and Susan Serruya

- **Technical contributions** (incl scoping)
  - Manzi Anatole, Rifat Atun, Himanshu Bhushan, Jacquelyn Caglia, Chompilas Chongsomchai, Morseda Chowdhury, Mengistu Hailemariam, Stephen Hodgins, Annie Kearns, Rajat Khosla, Ana Langer, Pisake Lumbiganon, Taiwo Oyelade, Jeffrey Smith, Petra ten Hoope-Bender, James Tielsch and Rownak Khan

- **Internal and external reviewers**
  - Andrea Bosman, Maurice Bucagu, Jahnavi Daru, Claudia Garcia-Moreno, Haileyesus Getahun, Rodolfo Gomez, Tracey Goodman, Tamar Kabakian, Avinash Kanchar, Philipp Lambach, Sarah de Masi, Frances McConville, Antonio Montresor, Justin Ortiz, Anayda Portela, Jeremy Pratt, Lisa Rogers, Nathalie Roos, Silvia Schwarte, Maria Pura Solon, João Paulo Souza, Petr Velebil, Ahmadu Yakubu, Yacouba Yaro, Teodora Wi and Gerardo Zamora

- **Observers**
  - France Donnay (BMGF), Rita Borg-Xuereb (ICM), Diogo Ayres-de-Campos and CN Purandare (FIGO), Luc de Bernis (UNFPA), Roland Kupka (UNICEF), Deborah Armbruster and Karen Fogg (USAID)

- **WHO ANC Technical Working Group**
  - Edgardo Abalos, Emma Allanson, Monica Chamillard, Virginia Diaz, Soo Downe, Kenny Finlayson, Claire Glenton, Ipek Gurol-Urganci, Sonja Henderson, Frances Kellie, Khalid Khan, Theresa Lawrie, Simon Lewin, Nancy Medley, Jenny Moberg, Charles O'Donovan, Ewelina Rogozinska and Inger Scheel
"To achieve the Every Woman Every Child vision and the Global Strategy for Women's Children's and Adolescents' Health, we need innovative, evidence-based approaches to antenatal care. I welcome these guidelines, which aim to put women at the centre of care, enhancing their experience of pregnancy and ensuring that babies have the best possible start in life."

Ban Ki-moon, UN Secretary-General
For further information

Dr Özge Tunçalp in RHR at tuncalpo@who.int
Dr Maurice Bucagu in MCA at bucagum@who.int
Dr Juan Pablo Peñas-Rosas in NHD at penarosasj@who.int